Aminopterin and compositions thereof for the treatment and / or prevention of inflammatory skin diseases

By using triamterene in combination with infliximab to treat psoriasis, the limitations of existing treatment methods have been overcome, achieving effective remission and improved safety in psoriasis.

CN119326766BActive Publication Date: 2026-06-12NANJING UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
NANJING UNIV
Filing Date
2024-10-17
Publication Date
2026-06-12

AI Technical Summary

Technical Problem

Existing treatments for psoriasis have limitations: topical treatments and phototherapy have limited effectiveness, systemic medications have serious side effects, biologics are expensive and carry a high risk of drug resistance, and there is a lack of effective and safe new treatment options.

Method used

Using triamterene or its pharmaceutically acceptable salt as the active ingredient, it is used to prepare medicines for the treatment and/or prevention of inflammatory skin diseases, particularly in combination with the TNF antagonist infliximab for the treatment of psoriasis.

Benefits of technology

It significantly relieves psoriasis symptoms, inhibits the abnormal proliferation of keratinocytes in the skin, improves epidermal thickening, inflammatory infiltration and erythematous scaling in the affected skin tissue, enhances efficacy and has good safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119326766B_ABST
    Figure CN119326766B_ABST
Patent Text Reader

Abstract

The present application provides the use of a compound of aminopterine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and / or preventing inflammatory skin diseases. Compared with the prior art, the following advantages are provided: the aminopterine, the compound thereof or the composition containing the same disclosed in the present application can be used for treating and / or preventing inflammatory skin diseases. The applicant first found that aminopterine can inhibit the abnormal proliferation of skin keratinocytes and skin inflammatory response, and significantly alleviate the symptoms of psoriasis. Through the study of a mouse psoriasis model induced by imiquimod, it was found that aminopterine can effectively improve the symptoms such as epidermal thickening, inflammatory infiltration and erythema scaling of the mouse skin lesion tissue. In addition, aminopterine combined with Infliximab for the treatment of psoriasis can significantly enhance the efficacy compared with the use of the two alone. It is shown that aminopterine can be used as an effective ingredient of a medicament to prepare a pharmaceutical preparation for the treatment of psoriasis.
Need to check novelty before this filing date? Find Prior Art